Takeda, XOMA ink new royalty agreement; amend existing deal
Source: SeekingAlpha
2025-12-30 08:14:57 ET
More on Takeda Pharmaceutical, XOMA
- Takeda: Lack Of Realistic Upside In Japanese Pharma
- Takeda Pharmaceutical Company Limited (TAK) Q2 FY2025 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited FY2025 Q2 - Results - Earnings Call Presentation
- Takeda posts late-stage trial win for oral plaque psoriasis therapy
- XOMA Royalty to acquire Generation Bio
Read the full article on Seeking Alpha
For further details see:
Takeda, XOMA ink new royalty agreement; amend existing deal
XOMA Royalty Corporation
NASDAQ: XOMA
XOMA Trading
-2.81% G/L:
$26.115 Last:
55,535 Volume:
$27.17 Open:
XOMA Latest News
March 12, 2026 06:30:00 am
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
February 09, 2026 09:53:00 am
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
December 30, 2025 07:30:00 am
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
XOMA Stock Data
$281,901,340
10,055,080
0.24%
24
N/A
Biotechnology & Life Sciences
Healthcare
US
Emeryville
